Back to top
more

Align Technology (ALGN)

(Delayed Data from NSDQ)

$236.97 USD

236.97
597,597

-1.09 (-0.46%)

Updated Oct 3, 2024 03:59 PM ET

After-Market: $232.00 -4.97 (-2.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 29% (178 out of 252)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

Haemonetics Banks on Solid Plasma & Haemonetics Management

Despite encouraging growth at the Plasma and Haemonetics Management franchises, the underperformance at the BloodCenter franchisee was quite a dampener for Haemonetics (HAE).

    Bio-Techne (TECH) Beats Earnings, Revenue Estimates in Q4

    Bio-Techne (TECH) rides high on strength in all three segments in Q4. Also, the company is focusing on product innovation through research and development.

      Nevro's (NVRO) Q2 Loss Wider than Expected, Revenues Beat

      Nevro's (NVRO) topline gains on continued global adoption of HF10 therapy. Rising operating expenses are major concerns.

        Focus on These 5 Top-Ranked Profitable Stocks in August

        Higher net income ratio usually implies a company's ability to generate ample revenue and successfully manage all its business functions.

          STERIS (STE) Beats on Q1 Earnings & Revenues, Margins Up

          STERIS' (STE) organic growth performance was strong across most segments in Q1. Robust cash position was another upside.

            BioScrip (BIOS) Q2 Loss Wider Than Expected, Revenues Miss

            BioScrip (BIOS) continues to disappoint in Q2 mainly due to its strategic shift to focus on growing its core revenue mix.

              BioTelemetry (BEAT) Q2 Earnings Top, Revenues Meet Estimates

              BioTelemetry (BEAT) rides high on all its segments in Q2. The company is also putting in efforts in product innovation through research and development.

                Myriad Genetics (MYGN) Beats on Q4 Earnings & Revenues

                Myriad Genetics (MYGN) rides high on strength in Molecular diagnostics with significant contributions from GeneSight. Also, hereditary cancer testing continues to witness sequential growth.

                  Penumbra (PEN) Loss Meets Estimates, Revenues Beat in Q2

                  Penumbra (PEN) witnessed strong growth across all its geographies and product lines in Q2. New product launches raise hope.

                    CVS Health (CVS) Q2 Earnings Beat, '17 Guidance Narrowed

                    CVS Health continues to grow (CVS) with Pharmacy Services business. However, its Retail/LTC sales drop.

                      Henry Schein (HSIC) Q2 Earnings & Revenues Beat, View Intact

                      Henry Schein (HSIC) maintained its stellar performance in Q2 as well, courtesy of strength in all of its business segments.

                        Orthofix (OFIX) Earnings Meet, Sales Beat Estimates in Q2

                        Orthofix (OFIX) rides high on strength in Biologics and Spine Fixation businesses. Moreover, raised full-year 2017 guidance buoys optimism.

                          Haemonetics (HAE) Q1 Earnings Beat, Revenues Miss Estimates

                          Haemonetics (HAE) rides high on Plasma and Haemonetics Management franchises strength in Q1.

                            Bio-Rad (BIO) Misses Q2 Earnings & Sales, Margin Declines

                            Bio-Rad's (BIO) sales declined on ERP-related disruption. Margin pressure continues.

                              Cardiovascular Systems Rides on Innovation Amid Several Woes

                              Cardiovascular Systems' (CSII) low operating expenses and strong revenue performance contributed to the upside in Q2 earnings.

                                Pacific Biosciences (PACB) Posts Wider-than-Expected Q2 Loss

                                Pacific Biosciences (PACB) posted a dull quarter with revenues declining in Q2. However, the company continues to anticipate 35% to 45% growth in product and service revenues for the year.

                                  Wright Medical Group (WMGI) Q2 Loss Narrower than Expected

                                  Wright Medical Group N.V. (WMGI) posted narrower-than-expected loss on account of strong growth in the U.S.

                                    Inogen (INGN) Beats Earnings and Revenue Estimates in Q2

                                    Inogen (INGN) delivers better-than-expected results in Q2 with significant contributions from the Business-to-Business segment. Moreover, raised guidance buoys optimism.

                                      Illumina (ILMN) Rides on New Products, Low Margin a Concern

                                      Illumina (ILMN) continues to grow in high-potential genetic research market through innovation and product launches.

                                        Bruker (BRKR) Q2 Earnings & Revenues Beat Estimates, View Up

                                        Bruker (BRKR) delivers a better-than-expected Q2, largely driven by strength in CALID Group and BEST. Moreover, a raised guidance buoys optimism.

                                          Kevin Cook headshot

                                          Bull of the Day: Align Technology (ALGN)

                                          The clear winner in alternative dental alignment continues to make long-term investors smile

                                            Hologic (HOLX) Beats on 3Q Earnings, Cuts Revenue Guidance

                                            Hologic's (HOLX) revenue growth in molecular diagnostics and GYN Surgical offset by poor blood screening and Breast Imaging show.

                                              Cardiovascular Systems (CSII) Posts Q4 Earnings, Revenues Top

                                              Cardiovascular Systems' (CSII) lower operating expenses drove the year-over-year improvement in Q4 earnings.

                                                Genomic Health (GHDX) Posts Wider-than-Expected Loss in Q2

                                                Genomic Health (GHDX) continues to lag expectations despite strong adoption of its Oncotype DX test.

                                                  Illumina (ILMN) Tops Q2 Earnings & Revenues, Raises View

                                                  Illumina (ILMN) delivers an impressive Q2 on strong uptake of sequencing consumables and microarrays and continued adoption of NovaSeq platform. A raised guidance buoys optimism.